MedTrace Logo

To Check Dermatological Safety of Test Products by 24 Hours Patch Testing

NCT07060976 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-09-17

No results posted yet for this study

Summary

To Check Dermatological Safety of Test Products by 24 Hours Patch Testing

Conditions

  • Healthy Participants

Interventions

OTHER

18 Transdermal patches along with positive and negative controls 1)Capsaicin0.025% Topical Patch, 2)Diclofenac Diethylamine 100mg Transdermal Patch, 3)Diclofenac Diethylamine 200mg Transdermal Patch,

Dose: 1×1 cm of each Patch (1 cm2) Route of administration: Topical Mode of usage: Products will be evaluated through the complete occlusion for 24 hours. At 24 hours post-application, patches will be removed and skin will be evaluated for irritation reactions at 30 mins,24 hours (Day 1)post patch removal and 168 hours (Day 7) post-patch removal (if needed). Frequency: single application

Sponsors & Collaborators

  • NovoBliss Research Pvt Ltd

    collaborator OTHER

  • Novamed Laboratories Pvt. Ltd.

    lead INDUSTRY

Principal Investigators

  • Nayan Patel · NovoBliss Research Private Limited

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-21
Primary Completion
2025-07-29
Completion
2025-07-29

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07060976 on ClinicalTrials.gov